The global Hypertrophic and Keloid Scar Treatment market size is expected to be worth around US$ 20.2 billion by 2030 from valued at US$ 5.8 billion in 2020 and is anticipated to grow at a CAGR of 11.9% during forecast period 2021 to 2030.
The global Hypertrophic and Keloid Scar Treatment market size is expected to be worth around US$ 20.2 billion by 2030 from valued at US$ 5.8 billion in 2020 and is anticipated to grow at a CAGR of 11.9% during forecast period 2021 to 2030.
Report Highlights
- Based on scar type, keloid scar dominated the market in 2021, with a total market share of 64.86%.
- Keloid scars are projected to witness the fastest growth rate at a CAGR of 8.78% during the forecast period.
- Hypertrophic scar type is projected to witness a considerably slow growth rate during the forecast time.
- The topical segment held the largest market share of more than 40.07% in the product segment.
- Laser segment is projected to witness the fastest growth rate over the forecast period.
- Based on end-use, the hospitals segment dominated the hypertrophic and keloid scar treatment market with a market share of more than 43.15% in the year 2021.
Immediate Delivery Available | Get the sample copy of report@ https://www.visionresearchreports.com/report/sample/37324
Growth Factors
Rise in awareness about esthetic appeal has led to the market growth. According to Plastic Surgery Statistics Report, 182,321 reconstructive procedures for scar revision were performed in 2017. Hence, the demand for reconstructive procedures also plays an important role in boosting the market growth.
Rise in burn injury cases has also led to increased demand for hypertrophic and keloid scar treatments. Plastic surgeries or resurfacing laser therapies are commonly performed to remove these marks. Hypertrophic burn marks can affect a victim’s appearance and are associated with other conditions, such as pruritis and contractures.
Scar Type Insights
Based on scar type, keloid scar dominated the market in 2021, with a total market share of 64.86%. Moreover, keloid scars are projected to witness the fastest growth rate at a CAGR of 8.78% during the forecast period. Keloid scars extend beyond the wound area and may become large. Furthermore, these scars are harder to heal and have a high return rate. For instance, as per Medscape, keloid scars treated with simple excision have a recurrence rate of 50-80%.
Additionally, keloid scars have a high risk of changing to cancer cells. On top of that, these scars do not heal on their own and never go away without treatment. Moreover, according to the American Osteopathic College of Dermatology, it is estimated that around 10% of people may witness keloid scars. Thus, due to the aforementioned factors, the keloid scar type is expected to dominate & witness the fastest growth rate over the forecast period.
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/37324
However, the hypertrophic scar type is projected to witness a considerably slow growth rate during the forecast time. This can be attributed to the characteristics of hypertrophic scars. Hypertrophic scars stay within the wound area. Moreover, these are less frequently seen and easier to treat as compared to keloid scars. Furthermore, unlike keloid scars, hypertrophic scars may become less noticeable with time, as a result, many people avoid treating them. Hence, due to the above-mentioned factors, hypertrophic scars are anticipated to witness a comparatively slow growth rate.
Product Insights
Based on product, the topical segment held the largest market share of more than 40.07% in the product segment. This dominance can be attributed to the rising use of topical products such as creams, silicone sheets, and gels on hypertrophic & keloid scars. These topical products are simply available to customers as over-the-counter (OTC) products, as a result, these are bought frequently. Moreover, these products do not need a person to visit any physicians for medication, thus, has become an easy and affordable alternative. Therefore, due to the aforementioned factors, the topical products segment is anticipated to dominate the industry during the period in focus.
However, the laser segment is projected to witness the fastest growth rate over the forecast period. This can be attributed to the advantages laser treatment provide to a patient. For instance, laser treatment resolves deep pitting and scarring. Moreover, the laser treatment is less harsh than traditional methods and is safe for all skin types & scar types. Furthermore, a study conducted at Medscape reported an average improvement of 77% after 1.8 laser treatments of hypertrophic scars. Thus, owing to the above-mentioned reasons, the laser product treatment is estimated to witness the fastest growth rate over the forecast period.
End-use Insights
Based on end-use, the hospitals segment dominated the hypertrophic and keloid scar treatment market with a market share of more than 43.15% in the year 2021. This can be credited to an increase in the number of hospital admissions and a rise in the number of hospitals globally. For instance, as per a study published by the American Hospital Association 2022 edition, the hospital count in the U.S. was calculated to be approximately 6,093 in 2020.
Similarly, as per the Centers for Disease Control and Prevention, the emergency department visit rate in the U.S. due to motor vehicle crashes was estimated to be 5.3 visits per 1,000 persons. Thus, with such an increase in the number of hospitals & hospital admissions due to road accidents, the hypertrophic and keloid scar treatment market is anticipated to propel over the forecast period.
Key Players
Smith & Nephew PLC; Enaltus, LLC; Merz, Inc.; Lumenis; Sonoma Pharmaceuticals; Cynosure, Inc.; Scar Heal, Inc.; Mölnlycke Health Care AB; Perrigo Company plc; NewMedical Technology, Inc.; Suneva Medical, Inc.; and Pacific World Corporation.
Market Segmentation
- Scar Type Outlook
- Hypertrophic
- Keloid
- Product Outlook
- Topical Products
- Silicone Sheets
- Creams
- Gels
- Others
- Laser products
- Pulse-dyed
- CO2
- Others
- Injectable
- Others
- Topical Products
- End-Use Outlook
- Hospitals
- Clinics
- Retail Pharmacies/E-commerce
- Regional Outlook
- North America
- U.S.
- Canada
- Europe
- Germany
- U.K.
- Asia Pacific
- Japan
- China
- India
- Latin America
- Brazil
- Mexico
- MEA
- South Africa
- North America
Immediate Delivery Available | Buy this Premium Research Report@ https://www.visionresearchreports.com/report/cart/37324
You can place an order or ask any questions, please feel free to contact at sales@visionresearchreports.com | +1 9197 992 333